Thrombocytopenia is the condition where in which the patient has a low platelet count. The root cause for the thrombocytopenia are the platelet splenic sequestration, inefficiency in the production of the platelets and the destruction of the platelets. Thrombocytopenia is either inherited or acquired. It usually occurs owing to various disorders such as leukemia and immune system related conditions. This is commonly found in both adults and children. In thrombocytopenia condition show very less symptoms and is mild. In some cases, the count of the platelets is so low that it causes dangerous internal bleeding, as the patient affected with the thrombocytopenia leads to delayed blood clotting or sometimes no blood clotting.
Increase in the prevalence of thrombocytopenia all across the globe and rising count of the chronic hepatitis C cases, which causes the risk of thrombocytopenia are likely to drive the growth of the market. The growing government support by financial aids to the patients in developing and under developed countries expected to drive the market revenue growth over forecast period. However, the stringent government regulations for approvals of newer treatments and increasing introduction of the generic drugs may hinder the growth of the market.
Geographically, global thrombocytopenia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America thrombocytopenia treatment market is growing due to increase in the prevalence of thrombocytopenia. The deep-rooted healthcare infrastructure is also anticipated to drive the growth of the market in the region. The awareness among the patient population regarding the new treatment methods is likely to enhance the growth of the market in the region. The adoption of the new treatment procedures by the patient pool is boosting the growth of the thrombocytopenia treatment market in the region.
In February 2018, Shionogi & Co., Ltd announced that the New Drug Application (NDA) for lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, has been accepted for filing and has been granted Priority Review by the U.S. Food & Drug Administration (FDA)
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
